June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 64–73 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen, Y.-J., Abila, B. & Kamel, Y. M. CAR-T: what is next? Cancers 15, 663 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Molina, J. C. et al. Absolute lymphocyte count recovery following initial acute myelogenous leukemia therapy: implications for adoptive cell therapy. Pediatr. Blood Cancer 70, e30062 (2023).

Article  CAS  PubMed  Google Scholar 

Das, R. K., Vernau, L., Grupp, S. A. & Barrett, D. M. Naïve T-cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers. Cancer Discov. 9, 492–499 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Singh, N., Perazzelli, J., Grupp, S. A. & Barrett, D. M. Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies. Sci. Transl. Med. 8, 320ra3 (2016).

Article  PubMed  Google Scholar 

Labanieh, L. & Mackall, C. L. CAR immune cells: design principles, resistance and the next generation. Nature 614, 635–648 (2023).

Article  CAS  PubMed  Google Scholar 

Hou, A. J., Chen, L. C. & Chen, Y. Y. Navigating CAR-T cells through the solid-tumour microenvironment. Nat. Rev. Drug. Discov. 20, 531–550 (2021).

Article  CAS  PubMed  Google Scholar 

Ruella, M. et al. A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor-positive cells. Blood 135, 505–509 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Ruella, M. et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat. Med. 24, 1499–1503 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Diorio, C. & Teachey, D. T. Harnessing immunotherapy for pediatric T-cell malignancies. Expert. Rev. Clin. Immunol. 16, 361–371 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Levine, B. L., Miskin, J., Wonnacott, K. & Keir, C. Global manufacturing of CAR T cell therapy. Mol. Ther. Methods Clin. Dev. 4, 92–101 (2017).

Article  CAS  PubMed  Google Scholar 

Al Hadidi, S., Zangari, M. & van Rhee, F. Chimeric antigen receptor T-cell therapy in multiple myeloma-challenges and potential solutions. JAMA Oncol. 8, 823–824 (2022).

Article  PubMed  Google Scholar 

Kourelis, T. et al. Ethical challenges with multiple myeloma BCMA chimeric antigen receptor T cell slot allocation: a multi-institution experience. Transpl. Cell Ther. 29, 255–258 (2023).

Article  Google Scholar 

Cliff, E. R. S. et al. High cost of chimeric antigen receptor T-cells: challenges and solutions. Am. Soc. Clin. Oncol. Educ. Book 43, e397912 (2023).

Article  PubMed  Google Scholar 

Chong, E. A. et al. CAR T cell viability release testing and clinical outcomes: is there a lower limit? Blood 134, 1873–1875 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Aldoss, I. et al. Favorable activity and safety profile of memory-enriched CD19-targeted chimeric antigen receptor T-cell therapy in adults with high-risk relapsed/refractory ALL. Clin. cancer Res. 29, 742–753 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lynn, R. C. et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature 576, 293–300 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Depil, S., Duchateau, P., Grupp, S. A., Mufti, G. & Poirot, L. Off-the-shelf’ allogeneic CAR T cells: development and challenges. Nat. Rev. Drug. Discov. 19, 185–199 (2020).

Article  CAS  PubMed  Google Scholar 

Borgert, R. Improving outcomes and mitigating costs associated with CAR T-cell therapy. Am. J. Manag. Care 27, 253–261 (2021).

Article  Google Scholar 

Fiorenza, S., Ritchie, D. S., Ramsey, S. D., Turtle, C. J. & Roth, J. A. Value and affordability of CAR T-cell therapy in the United States. Bone Marrow Transpl. 55, 1706–1715 (2020).

Article  Google Scholar 

Lyman, G. H., Nguyen, A., Snyder, S., Gitlin, M. & Chung, K. C. Economic evaluation of chimeric antigen receptor T-cell therapy by site of care among patients with relapsed or refractory large B-cell lymphoma. JAMA Netw. Open 3, e202072 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Ruella, M. & Kenderian, S. S. Next-generation chimeric antigen receptor T-cell therapy: going off the shelf. BioDrugs 31, 473–481 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chiesa, R. et al. Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia. N. Engl. J. Med. 389, 899–910 (2023).

Article  CAS  PubMed  Google Scholar 

Valton, J. et al. A multidrug-resistant engineered CAR T cell for allogeneic combination immunotherapy. Mol. Ther. 23, 1507–1518 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fabrizio, V. A. et al. Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. Blood Adv. 6, 1961–1968 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dekker, L. et al. Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia. Blood Adv. 6, 1969–1976 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qasim, W. Genome-edited allogeneic donor “universal” chimeric antigen receptor T cells. Blood 141, 835–845 (2023).

Article  CAS  PubMed  Google Scholar 

Morris, E. C. et al. Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications. Blood 102, 404–406 (2003).

Article  CAS  PubMed  Google Scholar 

Rebello, P. et al. Pharmacokinetics of CAMPATH-1H in BMT patients. Cytotherapy 3, 261–267 (2001).

Article  CAS  PubMed  Google Scholar 

Carpenter, B. et al. Incidence and dynamics of Epstein-Barr virus reactivation after alemtuzumab-based conditioning for allogeneic hematopoietic stem-cell transplantation. Transplantation 90, 564–570 (2010).

Article  CAS  PubMed  Google Scholar 

Beljanski, V. in xPharm: The Comprehensive Pharmacology Reference (eds Enna, S. J. & Bylund, D. B.) 1–4 (Elsevier, 2007).

Dupouy, S. et al. Clinical pharmacology and determinants of response to UCART19, an allogeneic anti-CD19 CAR-T cell product, in adult B-cell acute lymphoblastic leukemia. Cancer Res. Commun. 2, 1520–1531 (2022).

Article  CAS  PubMed  PubMed Central  Google